Additionally, Talabostat, a small-molecule dipeptidyl peptidase inhibitor targeting FAPα, has shown concentration-dependent suppression of activated fibroblast viability in both healthy and SSc fibroblasts, while also inhibiting fibroblast migration in SSc patients (Pashaei et al., 2024). The gene discussed is FAP; the disease is systemic sclerosis.